--- title: "Pediatric B-Lymphoblastic Leukemia COG AALL1732 | Sutter Health" description: "A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLyLy" url: "https://www.sutterhealth.org/research/clinical-trials/cogaall1732-1049141808" --- 1. [Home](https://www.sutterhealth.org/) / 2. [Research](https://www.sutterhealth.org/research) / 3. [Clinical trials](https://www.sutterhealth.org/research/clinical-trials) / 4. Pediatric B-Lymphoblastic Leukemia COG AALL1732 # Pediatric B-Lymphoblastic Leukemia COG AALL1732 **Status:** Open to Enrollment [Email us to enroll](https://www.sutterhealth.org/research/clinical-trials/cogaall1732-1049141808#enroll) #### Study details View study details on [www.clinicaltrials.gov](https://www.clinicaltrials.gov/ct2/show/NCT03959085). #### Locations - Sacramento #### Clinical trial FAQs Information for patients and study volunteers, including [frequently asked questions](https://www.sutterhealth.org/research/faqs). This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated with high-risk ALL chemotherapy. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first two phases of therapy: Induction and Consolidation. This part will collect information on the leukemia, as well as the effects of the initial treatment, in order to classify patients into post-consolidation treatment groups. On the second part of this study, patients will receive the remainder of the chemotherapy cycles (interim maintenance I, delayed intensification, interim maintenance II, maintenance), with some patients randomized to receive inotuzumab. Other aims of this study include investigating whether treating both males and females with the same duration of chemotherapy maintains outcomes for males who have previously been treated for an additional year compared to girls, as well as to evaluate the best ways to help patients adhere to oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy. ![Sandra K Baril, M.D.](https://dyn.mktgcdn.com/p/LeDczJiBVc-OKMwdWQTzaO-WX-HJKEXWeWf47e1fMY4/fit=crop,gravity=auto,dpr=2,width=188,height=250,quality=100) Sandra K Baril, M.D. Principal investigator [View profile](https://www.sutterhealth.org/research/investigators/sandra-k-baril-md-2016036488) ## Sub-Investigators [Saunders C Hsu, M.D., MPH](https://www.sutterhealth.org/research/investigators/saunders-c-hsu-md-mph-1049681145) , [Rachel Bito, M.D.](https://www.sutterhealth.org/research/investigators/rachel-bito-md-2070392186) , [Janice K Ryu, M.D.](https://www.sutterhealth.org/research/investigators/janice-k-ryu-md-2016036552) ## Email us to enroll - [Email Sacramento](mailto:ClinicalResearch%40sutterhealth.org?subject=More%20information%20on%20Pediatric%20B-Lymphoblastic%20Leukemia%20COG%20AALL1732%20in%20Sacramento&body=Please%20be%20aware%20that%20if%20you%20reply%20with%20unencrypted%20email%2C%20this%20increases%20the%20risk%20that%20information%20could%20be%20read%20by%20an%20unauthorized%20third%20party.%20Please%20do%20not%20include%20any%20Protected%20Health%20Information%20in%20your%20email%20response.) ## Related clinical trials [View all clinical trials](https://www.sutterhealth.org/research-search-results?verticalKey=clinical_trial) - Clinical trial ### [Pediatric Cancer Project Every Child APEC14B1](https://www.sutterhealth.org/research/clinical-trials/pediatric-cancer-project-every-child-apec14b1-1049141838) The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study **Status:** Open to Enrollment - Clinical trial ### [Pediatric Long Term Follow Up ALTE05N1](https://www.sutterhealth.org/research/clinical-trials/cogalte05n1-1049141846) Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies **Status:** Open to Enrollment - Clinical trial ### [Acute Myeloid Leukemia Dental Wipes COG ACCL2531](https://www.sutterhealth.org/research/clinical-trials/acute-myeloid-leukemia-dental-wipes-cog-accl2531-2099128841) A Randomized Double-Blinded Trial of Xylitol Dental Wipes for the Prophylaxis of Bloodstream Infections From Oral Organisms in Pediatric Patients With Acute Myeloid Leukemia **Status:** Open to Enrollment - Clinical trial ### [Neoadjuvant Hodgkin Lymphoma COG AHOD2131](https://www.sutterhealth.org/research/clinical-trials/neoadjuvant-hodgkin-lymphoma-cog-ahod2131-2080025103) A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy With Immuno-oncology Therapy for Children and Adults With Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma **Status:** Open to Enrollment - Clinical trial ### [Neoadjuvant Pediatric Leukemia AALL1821](https://www.sutterhealth.org/research/clinical-trials/neoadjuvant-pediatric-leukemia-aall1821-1049141818) A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old With First Relapse. **Status:** Open to Enrollment [View all clinical trials](https://www.sutterhealth.org/research-search-results?verticalKey=clinical_trial) ```json {"@context":"https://schema.org","@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org","logo":"https://www.sutterhealth.org/static/images/sutter-health-logo.svg","address":{"@type":"PostalAddress","streetAddress":"2200 River Plaza Drive","addressLocality":"Sacramento","addressRegion":"CA","postalCode":"95833","addressCountry":"US"},"areaServed":{"@type":"AdministrativeArea","name":"California"},"sameAs":["https://www.facebook.com/SutterHealth","https://www.instagram.com/sutterhealth/","https://x.com/SutterHealth","https://www.youtube.com/sutterhealth","https://www.linkedin.com/company/sutter-health","https://en.wikipedia.org/wiki/Sutter_Health"]} ``` ```json {"@context":"https://schema.org","@type":"BreadcrumbList","@id":"https://www.sutterhealth.org/research/clinical-trials/cogaall1732-1049141808#breadcrumblist","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://www.sutterhealth.org/"},{"@type":"ListItem","position":2,"name":"Research","item":"https://www.sutterhealth.org/research"},{"@type":"ListItem","position":3,"name":"Clinical trials","item":"https://www.sutterhealth.org/research/clinical-trials"},{"@type":"ListItem","position":4,"name":"Pediatric B-Lymphoblastic Leukemia COG AALL1732"}]} ``` ```json {"@context":"https://schema.org","@type":"MedicalWebPage","@id":"https://www.sutterhealth.org/research/clinical-trials/cogaall1732-1049141808#medicalwebpage","name":"Pediatric B-Lymphoblastic Leukemia COG AALL1732","description":"A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLyLy","url":"https://www.sutterhealth.org/research/clinical-trials/cogaall1732-1049141808","inLanguage":"en-US","dateModified":"2026-08-11","publisher":{"@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org"},"medicalAudience":{"@type":"MedicalAudience","audienceType":"Patient"},"mainEntity":{"@id":"https://www.sutterhealth.org/research/clinical-trials/cogaall1732-1049141808#medicaltrial"},"breadcrumb":{"@id":"https://www.sutterhealth.org/research/clinical-trials/cogaall1732-1049141808#breadcrumblist"},"mentions":[{"@type":"Person","name":"Sandra K Baril, M.D.","url":"https://www.sutterhealth.org/research/investigators/sandra-k-baril-md-2016036488","jobTitle":"Principal Investigator","affiliation":{"@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org"}}]} ``` ```json {"@context":"https://schema.org","@type":"MedicalTrial","@id":"https://www.sutterhealth.org/research/clinical-trials/cogaall1732-1049141808#medicaltrial","name":"Pediatric B-Lymphoblastic Leukemia COG AALL1732","alternateName":"A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLyLy","url":"https://www.sutterhealth.org/research/clinical-trials/cogaall1732-1049141808","description":"This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated with high-risk ALL chemotherapy. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first two phases of therapy: Induction and Consolidation. This part will collect information on the leukemia, as well as the effects of the initial treatment, in order to classify patients into post-consolidation treatment groups. On the second part of this study, patients will receive the remainder of the chemotherapy cycles (interim maintenance I, delayed intensification, interim maintenance II, maintenance), with some patients randomized to receive inotuzumab. Other aims of this study include investigating whether treating both males and females with the same duration of chemotherapy maintains outcomes for males who have previously been treated for an additional year compared to girls, as well as to evaluate the best ways to help patients adhere to oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.","identifier":"NCT03959085","code":{"@type":"MedicalCode","codeValue":"NCT03959085","codingSystem":"ClinicalTrials.gov"},"sameAs":"https://www.clinicaltrials.gov/ct2/show/NCT03959085","status":"https://schema.org/Recruiting","healthCondition":[{"@type":"MedicalCondition","name":"Leukemia, Pediatric"},{"@type":"MedicalCondition","name":"Lymphoma, Pediatric"}],"studyLocation":[{"@type":"AdministrativeArea","name":"Sacramento"}]} ```